CLINICAL AND EPIDEMIOLOGICAL MANIFESTATION OF HEPATOCELLULAR CARCINOMA IN PATIENTS BELONGING TO ETHNIC GROUPS OF CAUCASIANS AND ASIANS OF NORTH-EAST ASIA

Cover Page


Cite item

Full Text

Abstract

Aim. The current study is aimed at determining differences of epidemiological and clinical profiles associated with HCC in patients belonging to ethnic groups of Asians from Mongolia and Caucasians from Asian region of Russia. Materials and methods. The studies were carried out in the cross-border regions of Mongolia and Asian part of Russia (Irkutsk region). 300 patients with hepatocellular carcinoma (HCC) of the Caucasian and Mongolian races were enrolled in the study. The level of alpha-fetoprotein (AFP) in the serum was determined by the chemiluminescence technique. Results. The long-term dynamics of the HCC incidence shows more unfavourable trends in the territory of Mongolia compared to Irkutsk region. In both groups, male patients over 60 years of age predominated. Patients from Mongolia often have a history of jaundice and alcohol abuse. Out of the etiological factors, HCC is more often associated with the hepatitis B virus in Mongolia than in the Asian part of Russia. At the same time, in Caucasians, HCC develops primarily on the background of liver cirrhosis. In patients with HCC, AFP level higher than 20 ng / ml were significantly more frequent in the ethnic group of Caucasoids than in Mongoloids. Conclusions. Mongolia in terms of the incidence of HCC belongs to the hyperendemic regions of the world. In this country, among the risk factors for the development of the disease, hepatitis B virus plays a major role, which significantly differs from the Asian part of Russia. For the purpose of early diagnosis of HCC, it is necessary to search for new molecular markers or their combinations due to the insufficient diagnostic efficiency of AFP determination.

About the authors

N. D. Yuschuk

Moscow State University of Medicine and Dentistry

Author for correspondence.
Russian Federation

I. V. Malov

Irkutsk State Medical University

Russian Federation

O. .. Baatarkhuu

Mongolian National University of Medical Sciences

Russian Federation

E. D. Savilov

Scientific Centre of Family Health and Human Reproduction, Irkutsk State Medical Academy of Continuing Education

Russian Federation

S. I. Malov

Irkutsk State Medical University, Irkutsk State Medical Academy of Continuing Education

Russian Federation

R. I. Rasulov

Irkutsk State Medical University

Russian Federation

V. V. Dvornichenko

Irkutsk State Medical University

Russian Federation

T. .. Lkhagva-Ochir

National Cancer Centre of Mongolia

Russian Federation

J. .. Amarsanaa

Mongolian Association for the Study of Liver Diseases

Russian Federation

T. .. Decaens

Institut pour l’Avancee des Biosciences

Russian Federation

P. N. Marche

Institut pour l’Avancee des Biosciences

Russian Federation

References

  1. Бредер В.В., Косырев В.Ю., Кудашкин Н.Е., Лактионов К.К. Гепатоцеллюлярный рак в Российской Федерации как социальная и медицинская проблема. Медицинский совет. 2016, 10: 10-8.
  2. Кручкин Ю.Н. Современная Монголия. Энциклопедический справочник. Улан-Батор, 2011.
  3. Сергеев М.Н., Шевалдин А.Г., Рахманова А.Г., Слепцова С.С., Ляшенко Е.А., Шаройко В.В. Молекулярные маркеры гепатоцеллюлярной карциномы. Перспективы ранней диагностики. ВИЧ-инфекция и иммуносупрессия. 2014, 6(3): 16-23.
  4. Статистический бюллетень. Итоги всероссийской переписи населения 2010 года по Иркутской области. Иркутск: Иркутскстат, 2012.
  5. Baatarkhuu O., Kim D.Y., Bat-Ireedui P., Han K.H. Current situation of hepatocellular carcinoma in Mongolia. Oncology. 2011, 81 Suppl 1: 148-151.
  6. Babor T., Higgins-Biddle J.C., Saunders J.B., Monteiro M.G. AUDIT - The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care (2nd edn). Geneva: World Health Organization, 2001.
  7. But D.Y., Lai C.L., Yuen M.F. Natural history of hepatitis-related hepatocellular carcinoma. World J. Gastroentelol. 2008, 14(11): 1652-1656.
  8. Cole P., Morrison A.S. Basic issues in population screening for cancer. J. Natl. Cancer Inst. 1980, 64(5): 1263-1272.
  9. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol. 2018; 69(1): 182-236.
  10. Global hepatitis report 2017. Geneva: World Health Organization, 2017.
  11. Parikh N.D., Fu S., Rao H. et al. Risk assessment of hepatocellular carcinoma in patients with hepatitis C in China and the USA. Dig. Dis. Sci. 2017, 62(11): 3243-3253.
  12. Raza S.A., Clifford G.M., Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. British J.Cancer. 2007, 96(7): 1127-1134.
  13. Trad D., Bibani N., Sabbah M. et al. Known new and emerging risk factors of hepatocellular carcinoma (review). Presse Med. 2017, 46(11): 1000-1007.
  14. Tsatsralt-Od B., Takahashi M., Nishizawa T. et al. Inoue J., Ulaankhuu D., Okamoto H. High prevalence of hepatitis B, C and delta virus infections among blood donors in Mongolia. Arch. Virol. 2005, 150(12): 2513-2528.
  15. Yapali S., Tosun N. Epidemiology and viral risk factors for hepatocellular carcinoma in the Eastern Mediterranean countries. Hepatoma Res. 2018, 4: 24-34.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Yuschuk N.D., Malov I.V., Baatarkhuu O..., Savilov E.D., Malov S.I., Rasulov R.I., Dvornichenko V.V., Lkhagva-Ochir T..., Amarsanaa J..., Decaens T..., Marche P.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.